Thrombolytic therapy

Advances in Internal Medicine

Volumn 44, Issue , 1999, Pages 311-325

  Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOPLASTY; CEREBROVASCULAR DISEASE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; LUNG EMBOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; VEIN THROMBOSIS;

ANGIOPLASTY; ARTERIAL OCCLUSIVE DISEASES; CEREBROVASCULAR DISORDERS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 0032602912     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397-402, 1986.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349-360, 1988.
3. Weaver WD, Cerqueira M, Hallstrom AP, et al: Prehospital-initiated vs hospital-initiated thrombolytic therapy: The Myocardial Infarction Triage and Intervention Trial. JAMA 270:1211-1216, 1993.
4. The GUSTO-1 Angiographie Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. NEngl JMed 329:1615-1622, 1993.
5. Califf RM, for the GUSTO-I Investigators: One-year results from the global utilization of streptokinase and TPA for occluded coronary arteries (GUSTO-I) trial. Circulation 94:1233-1238, 1996.
6. Simoons ML, Vos J, Tijssen JG, et al: Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 14:1609-1615, 1989.
7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1:753-770, 1992.
8. Gruppo Italiano per lo Studio della Sopravivenza neH'Infarto Miocardico: GISSI-2: A factorial randomised trial of alteplase verus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336:65-71, 1990.
9. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl /Med 329:673-682, 1993.
10. Purvis JA, McNeill AJ, Siddiqui RA, et al: Efficacy of 100 mg of doublebolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 23:6-10, 1994.
11. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators: A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 337:1124-1130, 1997.
12. Weaver WD: The role of thrombolytic drugs in the management of myocardial infarction: Comparative clinical trials. EUT Heart J 17 (Suppl F):9-15, 1996.
13. Reteplase (Retavase). Med Lett Drugs Ther 39:17-18, 1997.
14. International Joint Efficacy Comparison of Thrombolytics: Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 346:329-336, 1995.
15. Bode C, for the RAPID II Investigators: Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 94:891-898, 1996.
16. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118-1123, 1997.
17. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO lib) Angioplasty Substudy Investigators: A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336:1621-1628, 1997.
18. Cannon CP, Braunwald E: Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. / Thromb Thrombolysis 3:117-125, 1996.
19. Cannon CP, and the TIMI10A Investigators: TNK-Tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial. Circulation 95:351-356, 1997.
20. Vanderschueren S, Dens J, Kerdsinchai P, et al: Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 134:213-219, 1997.
21. Kasper W, Konstantinides S, Geibel A, et al: Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. / Am Coll Cardiol 30:1165-1171, 1997.
22. Konstantinides S, Geibel A, Olschewski M, et al: Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a Multicenter Registry. Circulation 96:882-888, 1997.
23. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al: Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as predictor of mortality. Am Heart J 134:479-487, 1997.
24. Goldhaber SZ, De Rosa M, Visani L: International Cooperative Pulmonary Embolism Registry detects high mortality rate. Circulation 96:1159A, 1997.
25. Goldhaber SZ, Kessler CM, Heit J, et al: A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 2:293-298, 1988.
26. Goldhaber SZ, Haire WD, Feldstein ML, et al: Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 341:507-511, 1993.
27. Daniels LB, Parker JA, Patel SR, et al: Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am }Cardiol 80:184-188, 1997.
28. Kanter DS, Mikkola KM, Patel SR, et al: Thrombolytic therapy for pulmonary embolism: Frequency of intracranial hemorrhage and associated risk factors. Chest 111:1241-1245, 1997.
29. Mikkola KM, Patel SR, Parker JA, et al: Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 134:69-72, 1997.
30. Greenfield LJ, Proctor MC, Williams DM, et al: Long-term experience with transvenous catheter pulmonary embolectomy. / Vase Surg 18:450-458, 1993.
31. Gulba DC, Schmid C, Borst H-G, et al: Medical compared with surgical treatment for massive pulmonary embolism. Lancet 343:576-577, 1994.
32. Fava M, Loyola S, Flores P, et al: Mechanical fragmentation and pharmacologie thrombolysis in massive pulmonary embolism. / Vase Interv Radial 8:261-266, 1997.
33. Goldhaber SZ, Buring JE, Lipnick RJ, et al: Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am)Med 76:393-397, 1984.
34. O'Meara JJ III, McNutt RA, Evans AT, et al: A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 330:1864-1869, 1994.
35. Brown WD, Goldhaber SZ: How to select patients with deep vein thrombosis for tPA therapy. Chest 95:2768-2788, 1989.
36. Markel A, Manzo RA, Strandness DE Jr: The potential role of thrombolytic therapy in venous thrombosis. Arch Intern Med 152:1265-1267, 1992.
37. Goldhaber SZ, Polak JF, Feldstein ML, et al: Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis. Am J Cardiol 73:75-79, 1994.
38. Goldhaber SZ, Hirsch DR, MacDougall RC, et al: Bolus recombinant urokinase versus heparin in deep venous thrombosis: A randomized controlled trial. Am Heart f 132:314-318, 1996.
39. Meyerovitz MF, Polak JF, Goldhaber SZ: Short-term response to thrombolytic therapy in deep venous thrombosis: Predictive value of venographic appearance. Radiology 184:345-348, 1992.
40. Bjarnason H, Kruse JR, Asinger DA, et al: Iliofemoral deep venous thrombosis: Safety and efficacy outcome during 5 years of catheterdirected thrombolytic therapy. / Vase Interv Radial 8:405-418, 1997.
41. Caplan LR: Stroke thrombolysis: Growing pains. Mayo Clin Proc 72:1090-1092, 1997.
42. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischémie stroke. N Engl J Med 333:1581-1587, 1995.
43. Grotta J: tPA: The best current option for most patients. N Engl J Med 337:1310-1313, 1997.
44. Tong DC, Yenari MA, Albers GW: Intravenous thrombolytic therapy in acute stroke. Vascular Medicine 2:51-60, 1997.
45. McNamara TO, Bomberger RA, Merchant RF: Intra-arterial urokinase as the initial therapy for acutely ischémie lower limbs. Circulation 83 (Suppl I):106-119, 1991.
46. Ouriel K, Shortell CK, DeWeese JA, et al: A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. / Vase Surg 19:1021-1030,1994.
47. The STILE Investigators: Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE Trial. Ann Surg 220:251-268, 1994.
48. Ouriel K, Veith FJ, Sasahara AA, for the TOPAS Investigators: Thrombolysis or peripheral arterial surgery: Phase I results. / Vase Surg 23:64-75, 1996.
49. Ouriel K, Veith FJ, Sasahara AA: A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs: Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engt f Med 338:1105-1111, 1998.